Cargando…

Isolation and Characterization of an Unknown Process-Related Impurity in Furosemide and Validation of a New HPLC Method

Furosemide is a widely used loop diuretic in the treatment of congestive heart failure and edema. During the preparation of furosemide, a new process-related impurity G in the levels ranging from 0.08% to 0.13% was detected in pilot batches by a new high performance liquid chromatography (HPLC) meth...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Ao, Xue, Yunlin, Zeng, Yuyu, Li, Jing, Zhou, Huiling, Wang, Zhen, Chen, Yin, Chen, Hui, Jin, Jian, Zhuang, Tao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10005432/ https://www.ncbi.nlm.nih.gov/pubmed/36903659 http://dx.doi.org/10.3390/molecules28052415

Ejemplares similares

Identification, Isolation and Characterization of an Unknown Impurity of Varenicline
por: Satheesh, Balasubramanian, et al.
Publicado: (2012)

Validated HPLC-RI Method for the Determination of Lactulose and its Process Related Impurities in Syrup
por: Nelofar, A., et al.
Publicado: (2010)

Identification, synthesis and characterization of process related desfluoro impurity of ezetimibe and HPLC method validations()
por: Bellur Atici, Esen, et al.
Publicado: (2015)

Development of HPLC-CAD method for simultaneous quantification of nine related substances in ursodeoxycholic acid and identification of two unknown impurities by HPLC-Q-TOF-MS
por: Huang, Yiwen, et al.
Publicado: (2023)

Isolation, Identification, and Characterization of an Unknown Impurity in Lovastatin EP
por: Belwal, Chandrakant, et al.
Publicado: (2014)

Identification of Unknown Impurity of Azelaic Acid in Liposomal Formulation Assessed by HPLC-ELSD, GC-FID, and GC-MS
por: Han, Stanisław, et al.
Publicado: (2013)

A Fast and Validated HPLC Method for Simultaneous Determination of Dopamine, Dobutamine, Phentolamine, Furosemide, and Aminophylline in Infusion Samples and Injection Formulations
por: Chen, Fuchao, et al.
Publicado: (2021)

A Validated RP-HPLC Stability Method for the Estimation of Chlorthalidone and Its Process-Related Impurities in an API and Tablet Formulation
por: Kharat, Chaitali, et al.
Publicado: (2020)

Synthesis, isolation, identification and characterization of new process-related impurity in isoproterenol hydrochloride by HPLC, LC/ESI-MS and NMR
por: Kumar, Neeraj, et al.
Publicado: (2017)

Identification, synthesis and characterization of process related impurities of benidipine hydrochloride, stress-testing/stability studies and HPLC/UPLC method validations()
por: Bellur Atici, Esen, et al.
Publicado: (2015)

Development and Validation of Miglitol and Its Impurities by RP-HPLC and Characterization Using Mass Spectrometry Techniques
por: Balakumaran, Kesavan, et al.
Publicado: (2016)

Management of validation of HPLC method for determination of acetylsalicylic acid impurities in a new pharmaceutical product
por: Kowalska, Małgorzata, et al.
Publicado: (2022)

HPLC Method for Simultaneous Determination of Impurities and Degradation Products in Zonisamide
por: Vijayakumar, E. K. S., et al.
Publicado: (2009)

HPLC-Based Analysis of Impurities in Sapropterin Branded and Generic Tablets
por: Scudellaro, Emanuela, et al.
Publicado: (2020)

Validated HPLC–PDA methodology utilized for simultaneous determination of Etoricoxib and Paracetamol in the presence of Paracetamol toxic impurities
por: Abdel Rahman, Mona A., et al.
Publicado: (2022)

Development and Validation of a Stability-Indicating RP-HPLC Method for the Determination of Process-Related Impurities and Degradation Products of Rabeprazole Sodium in Pharmaceutical Formulation
por: Kumar, Navneet, et al.
Publicado: (2013)

Development and Validation of a Precise, Single HPLC Method for the Determination of Tolperisone Impurities in API and Pharmaceutical Dosage Forms
por: Raju, Thummala Veera Raghava, et al.
Publicado: (2013)

Development and Validation of a Stability-Indicating RP-HPLC Method for the Estimation of Drotaverine Impurities in API and Pharmaceutical Formulation
por: Thummala, Veera Raghava Raju, et al.
Publicado: (2014)

Isolation and Characterization of a Process Impurity in Tizanidine Hydrochloride
por: Vijayakumar, E. K. S., et al.
Publicado: (2010)

Cost-Effective Isolation of a Process Impurity of Pregabalin
por: Prakash, Lakkireddy, et al.
Publicado: (2015)

Gold and platinum in silicon-isolated impurities and impurity complexes
por: Burchard, A, et al.
Publicado: (1996)

Gold and platinum in silicon isolated impurities and impurity complexes
por: Burchard, A, et al.
Publicado: (1996)

An Experimental Design Approach for Impurity Profiling of Valacyclovir-Related Products by RP-HPLC
por: Katakam, Prakash, et al.
Publicado: (2014)

Application of HPLC with ELSD Detection for the Assessment of Azelaic Acid Impurities in Liposomal Formulation
por: Han, Stanislaw, et al.
Publicado: (2013)

Development and Validation of four Nitrosamine Impurities Determination Method in Medicines of Valsartan, Losartan, and Irbesartan with HPLC-MS/MS (APCI)
por: Khorolskiy, Mikhail, et al.
Publicado: (2021)

Development and Validation of Ecofriendly HPLC-MS Method for Quantitative Assay of Amoxicillin, Dicloxacillin, and Their Official Impurity in Pure and Dosage Forms
por: Almalki, Atiah H., et al.
Publicado: (2021)

A RP-HPLC Method for the Analysis of Neostigmine Methylsulfate and Process-Related Impurities, Forced Degradation Studies, in the Injection Formulation
por: Parab, Manali, et al.
Publicado: (2021)

Validated HPLC Method for Concurrent Determination of Antipyrine, Carbamazepine, Furosemide and Phenytoin and its Application in Assessment of Drug Permeability through Caco-2 Cell Monolayers
por: Patil, Sachin Ramrao, et al.
Publicado: (2012)

Electron paramagnetic resonance investigations of isolated impurities and impurity pairs in silicon
por: Burchard, A, et al.
Publicado: (1996)

An Insight into the Degradation Processes of the Anti-Hypertensive Drug Furosemide
por: Giannetti, Micaela, et al.
Publicado: (2023)

Size Exclusion HPLC Detection of Small-Size Impurities as a Complementary Means for Quality Analysis of Extracellular Vesicles
por: Huang, Tao, et al.
Publicado: (2015)

Stability profiling of anti-malarial drug piperaquine phosphate and impurities by HPLC-UV, TOF-MS, ESI-MS and NMR
por: Yan, Fang, et al.
Publicado: (2014)

Diuretic effect of co-administration of furosemide and albumin in comparison to furosemide therapy alone: An updated systematic review and meta-analysis
por: Lee, Tao Han, et al.
Publicado: (2021)

Stability-indicating HPLC-DAD/UV-ESI/MS impurity profiling of the anti-malarial drug lumefantrine
por: Verbeken, Mathieu, et al.
Publicado: (2011)

Development of the HPLC Method for Simultaneous Determination of Lidocaine Hydrochloride and Tribenoside Along with Their Impurities Supported by the QSRR Approach
por: Plenis, Alina, et al.
Publicado: (2012)

Identification of impurities in nafamostat mesylate using HPLC-IT-TOF/MS: A series of double-charged ions
por: Zhang, Yuxin, et al.
Publicado: (2020)

Cost-effective, green HPLC determination of losartan, valsartan and their nitrosodiethylamine impurity: application to pharmaceutical dosage forms
por: Abd El-Hay, Soad S., et al.
Publicado: (2022)

Unique Quality by Design Approach for Developing HPLC and LC-MS Method for Estimation of Process and Degradation Impurities in Pibrentasvir, Antiviral Agent for Hepatitis C
por: Vemuri, Divya Kumar, et al.
Publicado: (2022)

Oral Furosemide and Hydrochlorothiazide/Amiloride versus Intravenous Furosemide for the Treatment of Resistant Nephrotic Syndrome
por: Frățilă, Georgiana, et al.
Publicado: (2023)

A Validated HPLC/MS Limit Test Method for a Potential Genotoxic Impurity in Cilostazol and its Quantification in the API and in the Commercially Available Drug Product
por: Bray, Luigi, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_06ih2rtj6njp8eof60h81bif5b